Modifying brain cell activity can extend the lifespan of fruit flies while also preventing the damage characteristic of Alzheimer’s disease, finds a new study led by UCL researchers.

This is a detailed summary of plasma dilution and at 58:38 the future is explained where they will publish human results from 25 people, then start a company whose first order of business will be phase 3 trials with more people and placebo and hopefully funding. It appears you can pay to have the procedure. The hopeful start is this year in may.
Irina will present her recent findings on plasma dilution, showing that age-reversing effects, such as rejuvenating tissues in mice, can be achieved by.
diluting the blood plasma of old mice: Rejuvenation of three germ layers tissues by exchanging old blood plasma with saline-albumin.
Irina’s research focus.
A key direction of my laboratory is to understand age-imposed and pathological changes in molecular compositions of systemic and local environments of adult stem cells and to calibrate these to health — youth. In the past few years this direction has been ramified into synthetic biology, CRISPR technologies, bio-orthogonal proteomics and development of innovative digital bio-sensors that we collaboratively applied to the fields of aging and diagnostics of genetic diseases. Success in this research will improve our understanding of the determinants of homeostatic health and will enable novel rational approaches to treat a number of degenerative, fibrotic, metabolic and inflammatory diseases, as a class.
Zoom Transcription:
https://otter.ai/u/yhmNLEM7V52oOfW93lUfDWqL_uw
Join us for Dr. Matt Kaeberlein’s presentation. He is the Founding Director of the UW Healthy Aging and Longevity Research Institute, and founder and co-Director of the Dog Aging Project and a Professor of Laboratory Medicine and Pathology at the University of Washington (UW) School of Medicine, with Adjunct appointments in Genome Sciences and Oral Health Sciences. Dr. Kaeberlein’s research interests are focused on biological mechanisms of aging in order to facilitate translational interventions that promote healthspan and improve quality of life.
“Our task is to make nature, the blind force of nature, into an instrument of universal resuscitation and to become a union of immortal beings.“
- Nikolai F. Fedorov.
We hold faith in the technologies & discoveries of humanity to END AGING and Defeat involuntary Death within our lifetime.
Working to Save Lives with Age Reversal Education.
========== Perpetual Life Creed ==========
We believe that all of life is sacred and that we have been given this one life to make unlimited. We believe in our Creator’s divine plan for all of humanity to have infinite lifespans in perfect health and eternal joy, rendering death to be optional.
A trio of researchers with ICAEV, Universidad Austral de Chile, and the University of Liverpool, respectively, have found suppressor genes linked to longevity and less cancer in two species of whales. In their paper published in the journal Proceedings of the Royal Society B, Daniela Tejada-Martinez, João Pedro de Magalhães and Juan C. Opazo, describe their genetic study of longevity in cetaceans and what they learned.
https://www.biorxiv.org/content/10.1101/2020.05.07.082917v1.…e=youtu.be
Hi everybody. Around 10 days ago, I participated in an online conference about aging, organized by HEALES and ILA, and Harold Katcher was one of the speakers. As each speaker had only 15 minutes for their presentation (and Harold spoke only for 10 minutes because he had some technical issues with Zoom), I thought that it would be a good idea to make an interview with him so that he has more time to speak about his rejuvenation therapy with E-5, the test with dogs, the timeframe for the arrival of the therapy for humans, and, above all else, his theory of aging. So, it’s a more informal conversation, but I think it helps everybody to know more about Harold Katcher, maybe one of the most (if not the most) influent people in human history.
Harold Katcher, one of the discoverers of the human breast cancer gene and possibly the discoverer of the greatest rejuvenation therapy to date, talks to Nicolas Chernavsky about his rejuvenation therapy with E-5, his carreer and his theory of aging. 2020 paper on experiments with E-5: https://www.biorxiv.org/content/10.1101/2020.05.07.082917v1.…1.full.pdf Harold’s 2013 paper on aging: https://link.springer.com/article/10.1134/S0006297913090137 Conboy’s 2005 paper on parabiosis: https://www.biorxiv.org/content/10.1101/2020.05.07.082917v1.…ature03260 1994 paper on human breast cancer gene: https://courses.washington.edu/gs466/readings/miki.pdf Find out more about Nicolas Chernavsky and NTZ on www.ntzplural.com #rejuvenation #aging #biotechnology #health #science.
Muscle constitutes the largest organ in humans, accounting for 40% of body mass, and it plays an essential role in maintaining life. Muscle tissue is notable for its unique ability for spontaneous regeneration. However, in serious injuries such as those sustained in car accidents or tumor resection which results in a volumetric muscle loss (VML), the muscle’s ability to recover is greatly diminished. Currently, VML treatments comprise surgical interventions with autologous muscle flaps or grafts accompanied by physical therapy. However, surgical procedures often lead to reduced muscular function, and in some cases result in a complete graft failure. Thus, there is a demand for additional therapeutic options to improve muscle loss recovery.
A promising strategy to improve the functional capacity of the damaged muscle is to induce de novo regeneration of skeletal muscle via the integration of transplanted cells. Diverse types of cells, including satellite cells (muscle stem cells), myoblasts, and mesenchymal stem cells, have been used to treat muscle loss. However, invasive muscle biopsies, poor cell availability, and limited long-term maintenance impede clinical translation, where millions to billions of mature cells may be needed to provide therapeutic benefits.
Companies that are creating rejuvenation biotechnology interventions must develop their products to target individual diseases in order to be approved by the FDA. While that is still the case, this particular FOA is intended to promote broader research that does not necessarily target individual diseases as endpoints.
The National Institutes of Aging in the United States, a component of the National Institutes of Health, is funding clinical trials for interventions that directly affect the root causes of age-related diseases.
Direct funding for trials against aging
Probably the most important and interesting part of this Funding Opportunity Announcement (FOA) is that the NIA specifically mentions “multiple chronic conditions” caused by the processes of aging along with more conventional trials that are targeted directly at specific downstream effects of aging.